261 related articles for article (PubMed ID: 12393675)
1. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
[TBL] [Abstract][Full Text] [Related]
2. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
[TBL] [Abstract][Full Text] [Related]
3. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
4. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope.
Campi G; Crosti M; Consogno G; Facchinetti V; Conti-Fine BM; Longhi R; Casorati G; Dellabona P; Protti MP
Cancer Res; 2003 Dec; 63(23):8481-6. PubMed ID: 14679013
[TBL] [Abstract][Full Text] [Related]
5. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
6. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.
Chaux P; Vantomme V; Stroobant V; Thielemans K; Corthals J; Luiten R; Eggermont AM; Boon T; van der Bruggen P
J Exp Med; 1999 Mar; 189(5):767-78. PubMed ID: 10049940
[TBL] [Abstract][Full Text] [Related]
7. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals.
Iwai LK; Yoshida M; Sidney J; Shikanai-Yasuda MA; Goldberg AC; Juliano MA; Hammer J; Juliano L; Sette A; Kalil J; Travassos LR; Cunha-Neto E
Mol Med; 2003; 9(9-12):209-19. PubMed ID: 15208742
[TBL] [Abstract][Full Text] [Related]
8. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
[TBL] [Abstract][Full Text] [Related]
9. The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.
Cecconi V; Moro M; Del Mare S; Sidney J; Bachi A; Longhi R; Sette A; Protti MP; Dellabona P; Casorati G
Eur J Immunol; 2010 Jun; 40(6):1603-16. PubMed ID: 20306469
[TBL] [Abstract][Full Text] [Related]
10. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.
Godefroy E; Wang Y; Souleimanian NE; Scotto L; Stevanovic S; Chen YT; Valmori D; Ayyoub M
Cancer Immunol Immunother; 2007 Aug; 56(8):1183-92. PubMed ID: 17186289
[TBL] [Abstract][Full Text] [Related]
11. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
12. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.
Ayyoub M; Hesdorffer CS; Montes M; Merlo A; Speiser D; Rimoldi D; Cerottini JC; Ritter G; Scanlan M; Old LJ; Valmori D
J Clin Invest; 2004 Apr; 113(8):1225-33. PubMed ID: 15085202
[TBL] [Abstract][Full Text] [Related]
13. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
15. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.
Vujanovic L; Mandic M; Olson WC; Kirkwood JM; Storkus WJ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6796-806. PubMed ID: 18006782
[TBL] [Abstract][Full Text] [Related]
16. The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles.
Reynolds CJ; Jones C; Blohmke CJ; Darton TC; Goudet A; Sergeant R; Maillere B; Pollard AJ; Altmann DM; Boyton RJ
Immunology; 2014 Nov; 143(3):438-46. PubMed ID: 24891088
[TBL] [Abstract][Full Text] [Related]
17. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
19. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
